Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.

Base Genomics logo

Base Genomics joined the BioEscalator in March 2020 after meeting stringent gateway criteria set by the BioEscalator Management Board, who recognised the company’s high growth potential. In 6 months, they have grown from one lab space to two labs and an office with a third lab soon to be occupied. The BioEscalator has been able to support this rapid expansion by providing flexible space and serviced facilities.

Base Genomics was co-founded in 2018 by two Oxford academics Dr Yibin Liu and Dr Chunxiao Song from the Ludwig Institute and OSI’s Entrepreneur in Residence, Oliver Waterhouse, now CEO at Base. Their aim was to focus on developing a simple blood test to detect early-stage cancers.

The underlying DNA methylation detection technology, TAPS, capable long-read DNA sequencing, was developed at the Ludwig Institute for Cancer Research by Drs Liu and Song. Base Genomics’ leadership team is completed by Oxford alumna Dr Vincent Smith and Prof Anna Schuh, who is also Director of Molecular Diagnostics at the University’s Department of Oncology.

The full story can be viewed on the BioEscalator website

Similar stories

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.

Oxford announces the founding of the new Bennett Institute for Applied Data Science

The Bennett Institute for Applied Data Science at the University of Oxford has been established to pioneer the better use of data, evidence and digital tools in healthcare and policy, optimizing the impact of interventions to achieve improved outcomes.